Phase 2 Efficacy Study of Primaquine and Methylene Blue
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the most efficacious transmission blocking drug
regimen for seasonal malaria chemoprophylaxis in Mali. The primary outcome measure will be
the proportion of mosquitoes infected pre and post-treatment, assessed through membrane
feeding and measured by oocyst prevalence in mosquitoes dissected on day 7 post feed. Primary
endpoint will be a within group comparison between the mean of the pretreatment infectivity
(Day 0) and infectivity at 7 days post first dose.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bill and Melinda Gates Foundation Heidelberg University London School of Hygiene and Tropical Medicine Malaria Research and Training Center, Bamako, Mali Radboud University
Treatments:
Amodiaquine Artemisinins Artenimol Dihydroartemisinin Fanasil, pyrimethamine drug combination Methylene Blue Piperaquine Primaquine Pyrimethamine Sulfadoxine